Michelle Wilson

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk, Christine Parkinson, Myong Cheol Lim et al. · Journal of Clinical Oncology · 2022 · 384 citations · Full text

Medicine, Oncology, Pharmacology +16

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Michelle Wilson, Éric Pujade-Lauraine, Daisuke Aoki et al. · Annals of Oncology · 2016 · 296 citations · Full text

Medicine, Gynecology, Oncology +16

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Bradley J. Monk, Robert L. Coleman, Keiichi Fujiwara et al. · International Journal of Gynecological Cancer · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia

Iván Díaz-Padilla, Michelle Wilson, Blaise Clarke et al. · Gynecologic Oncology · 2015 · 81 citations

Medicine, Oncology, Pharmacology +17

Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up

Michelle Wilson, Peter C.C. Fong, Soizick Mesnage et al. · Gynecologic Oncology · 2015 · 73 citations

Veterinary Medicine, Oncology, Surgery +8